Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100060 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01100060 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 40 participants.
The verdict
NCT01100060, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin (2000 mg) and chloroquine (600 mg CQ base) in healthy adult subjects.
Interventions
- DRUG azithromycin (AZ) microsphere
- DRUG test chloroquine (CQ) formulation
- DRUG azithromycin (AZ)
- DRUG chloroquine (CQ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100060
The ClinicalTrials.gov registry entry for NCT01100060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which azithromycin (AZ) microsphere is the first listed.
NCT01100060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01100060 about?
NCT01100060 is a clinical study titled "A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects". Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin (2000 mg) and chloroquine (600 mg CQ base) in healthy adult subjects.
What is the current status of trial NCT01100060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01100060?
The interventions under investigation include: azithromycin (AZ) microsphere (DRUG), test chloroquine (CQ) formulation (DRUG), azithromycin (AZ) (DRUG), chloroquine (CQ) (DRUG).
Who is sponsoring clinical trial NCT01100060?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.